201. Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.
- Author
-
Ye XY, Chen SY, Wu S, Yoon DS, Wang H, Hong Z, O'Connor SP, Li J, Li JJ, Kennedy LJ, Walker SJ, Nayeem A, Sheriff S, Camac DM, Ramamurthy V, Morin PE, Zebo R, Taylor JR, Morgan NN, Ponticiello RP, Harrity T, Apedo A, Golla R, Seethala R, Wang M, Harper TW, Sleczka BG, He B, Kirby M, Leahy DK, Li J, Hanson RL, Guo Z, Li YX, DiMarco JD, Scaringe R, Maxwell B, Moulin F, Barrish JC, Gordon DA, and Robl JA
- Subjects
- 11-beta-Hydroxysteroid Dehydrogenase Type 1 chemistry, 11-beta-Hydroxysteroid Dehydrogenase Type 1 metabolism, Actins antagonists & inhibitors, Adamantane administration & dosage, Adamantane chemistry, Adamantane pharmacology, Administration, Oral, Animals, Azetidines administration & dosage, Azetidines chemistry, Biological Availability, Crystallography, X-Ray, Dogs, Enzyme Inhibitors administration & dosage, Enzyme Inhibitors chemistry, Female, Half-Life, Humans, Hypothalamo-Hypophyseal System drug effects, Inhibitory Concentration 50, Macaca fascicularis, Male, Mice, Obese, Rats, Structure-Activity Relationship, 11-beta-Hydroxysteroid Dehydrogenase Type 1 antagonists & inhibitors, Adamantane analogs & derivatives, Azetidines pharmacology, Enzyme Inhibitors pharmacology
- Abstract
BMS-816336 (6n-2), a hydroxy-substituted adamantyl acetamide, has been identified as a novel, potent inhibitor against human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme (IC
50 3.0 nM) with >10000-fold selectivity over human 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). 6n-2 exhibits a robust acute pharmacodynamic effect in cynomolgus monkeys (ED50 0.12 mg/kg) and in DIO mice. It is orally bioavailable (%F ranges from 20 to 72% in preclinical species) and has a predicted pharmacokinetic profile of a high peak to trough ratio and short half-life in humans. This ADME profile met our selection criteria for once daily administration, targeting robust inhibition of 11β-HSD1 enzyme for the first 12 h period after dosing followed by an "inhibition holiday" so that the potential for hypothalamic-pituitary-adrenal (HPA) axis activation might be mitigated. 6n-2 was found to be well-tolerated in phase 1 clinical studies and represents a potential new treatment for type 2 diabetes, metabolic syndrome, and other human diseases modulated by glucocorticoid control.- Published
- 2017
- Full Text
- View/download PDF